Psoriasis comorbidity management in the COVID era: a pressing challenge

Yang Song; Lei Yao; Shanshan Li; Junfeng Zhou

doi:10.3389/fmicb.2023.1294056

Psoriasis comorbidity management in the COVID era: a pressing challenge

Front Microbiol. 2023 Nov 10:14:1294056. doi: 10.3389/fmicb.2023.1294056. eCollection 2023.

Authors

Yang Song¹, Lei Yao¹, Shanshan Li¹, Junfeng Zhou¹

Affiliation

¹ Department of Dermatology, Hospital of Jilin University, Changchun, China.

Abstract

The global COVID-19 pandemic has presented a significant, ongoing challenge since its emergence in late 2019. Today, the Omicron strain, which is less lethal but more contagious than the original outbreak strain, continues to pose substantial health risks. In this background, the management of psoriatic comorbidities has become even more complex, particularly for patients with underlying inflammatory, metabolic, or cardiovascular diseases. This review aims to summarize current research on comorbid COVID-19 and psoriasis, and provide insights into the development of evidence-based management strategies. By providing appropriate patient instruction, implementing protective measures, and re-evaluating medication prescriptions based on each patient's unique situation, healthcare professionals can effectively address the challenges faced by patients with comorbid psoriasis in the COVID-19 era.

Keywords: COVID-19; SARS-CoV-2; biologics; comorbidity; management; psoriasis.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was funded by the Natural Science Foundation of Jilin Province (Project nos. YDZJ202201ZYTS030 and 20220204095YY); and by the Jilin Provincial Healthcare Talent Special Program of Jilin Province Department of Finance (Project number JLSWSRCZX2021-67).